The Journal of Pediatrics
Volume 151, Issue 2 , Pages 108-110 , August 2007

Newborn Screening: The Spigot is Open and Threatens to Become a Flood

  • Stephen Cederbaum, MD

      Affiliations

    • Corresponding Author InformationReprint requests: Stephen Cederbaum, NRB 347, 635 Charles E Young Dr S, Los Angeles, CA 90095-7332.

References 

  1. Pollit RJ. International perspectives on newborn screening. J Inherit Metab Dis. 2006;29:390–396
  2. Haas M, Chaplin M, Joy P, Wiley V, Black C, Wilcken B. Healthcare use and costs of MCAD deficiency in Australia: screening versus no screening. J Pediatr. 2007;151:121–126
  3. van der Hilst CS, Derks TGJ, Reijngoud D-J, Smit PA, Ten Vergert EM. Cost-effectiveness of neonatal screening for medium-chain acyl-CoA dehydrogenase (MCAD) deficiency: the homogeneous population of the Netherlands. J Pediatr. 2007;151:115–120
  4. Venditti LN, Venditti CP, Berry GT, Kaplan PB, Kaye EM, Glick H, et al. Newborn screening by tandem mass spectrometryfor medium-chain acyl-CoA dehydrogenase deficiency: accost effectiveness analysis. Pediatrics. 2003;112:1005–1015
  5. Insinga RP, Laessig RH, Hoffman GL. Newborn screening with tandem mass spectrometry:examining its cost-effectiveness in the Wisconsin newborn screening panel. J.Pediatr. 2002;141:524–531
  6. Schoen EJ, Baker JC, Colby CJ, To TT. Cost-benefit analysis of universal tandem mass spectrometry for newborn screening. Pediatrics. 2002;110:781–786
  7. Meikle PJ, Grasby DJ, Dean CJ, Lang DL, Bockmann M, Whittle AM, et al. Newborn screening for lysosomal storage disorders. Mol Genet Metab. 2006;88:307–314

PII: S0022-3476(07)00365-4

doi: 10.1016/j.jpeds.2007.04.035

The Journal of Pediatrics
Volume 151, Issue 2 , Pages 108-110 , August 2007

Article Tools